Close

Anti-pp65 TCR-NK Cells (XS-0623-ZP86)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The genetically modified anti-pp65 TCR-NK cell is designed to target to the specific epitope-HLA complex. The TCR-NK is expected to show antigen-specific cytotoxicity against pp65 antigen via the introduced TCR were successfully produced.

  Add to Cart

Specifications

  • Cell Type
  • TCR-NK
  • Host Cell Type
  • Primary NK cells

TCR Design

  • Target
  • pp65
  • Common Name
  • pp65
  • Target Species
  • CMV
  • TCR-Host Animal
  • Human
  • Vector Name
  • pCDTCR1
  • Vector length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
Sub CAT. HLA TCR Clone Epitope  
XS-0623-ZP86-SUB1 HLA-A2 RA14 NLVPMVATV
XS-0623-ZP86-SUB2 HLA-B35 12 IPSINVHHY
XS-0623-ZP86-SUB3 HLA-A*0201 JG-9 NLVPMVATV
XS-0623-ZP86-SUB4 HLA-A*0201 JG-33 NLVPMVATV
XS-0623-ZP86-SUB5 HLA-A*0101 MD-19 YSEHPTFTSQY
XS-0623-ZP86-SUB6 HLA-B*3501 BF-33/BF-38 IPSINVHHY
XS-0623-ZP86-SUB7 HLA-A2.1 NLVPMVATV
XS-0623-ZP86-SUB8 HLA-A2 C7 NLVPMVATV
XS-0623-ZP86-SUB9 HLA-A2 C25 NLVPMVATV
XS-0623-ZP86-SUB10 HLA-A*02 CB-C159 NLVPMVATV
XS-0623-ZP86-SUB11 HLA-A*02 CB-C160 NLVPMVATV
XS-0623-ZP86-SUB12 HLA-A*02 CB-C161 NLVPMVATV
XS-0623-ZP86-SUB13 HLA-A*02 CB-C162 NLVPMVATV
XS-0623-ZP86-SUB14 HLA-A*02 CB-C163 NLVPMVATV
XS-0623-ZP86-SUB15 HLA-A*02 CB-C164 NLVPMVATV
XS-0623-ZP86-SUB16 HLA-A*02 CB-C165 NLVPMVATV
XS-0623-ZP86-SUB17 HLA-A*02 CB-C166 NLVPMVATV
XS-0623-ZP86-SUB18 HLA-A*02 CB-C167 NLVPMVATV
XS-0623-ZP86-SUB19 HLA-A*02 CB-C168 NLVPMVATV
XS-0623-ZP86-SUB20 HLA-A*02 CB-C169 NLVPMVATV
XS-0623-ZP86-SUB21 HLA-A*02 CB-C170 NLVPMVATV
XS-0623-ZP86-SUB22 HLA-A*02 CB-C171 NLVPMVATV
XS-0623-ZP86-SUB23 HLA-A*02 CB-C172 NLVPMVATV
XS-0623-ZP86-SUB24 HLA-A*02 CB-C173 NLVPMVATV
XS-0623-ZP86-SUB25 HLA-A*02 CB-C174 NLVPMVATV
XS-0623-ZP86-SUB26 HLA-A*02 CB-C175 NLVPMVATV
XS-0623-ZP86-SUB27 HLA-A*02 CB-C176 NLVPMVATV
XS-0623-ZP86-SUB28 HLA-A*02 CB-C177 NLVPMVATV
XS-0623-ZP86-SUB29 HLA-A*02 CB-C178 NLVPMVATV
XS-0623-ZP86-SUB30 HLA-A*02 CB-C179 NLVPMVATV
XS-0623-ZP86-SUB31 HLA-A*02 CB-C180 NLVPMVATV
XS-0623-ZP86-SUB32 HLA-A*02 CB-C181 NLVPMVATV
XS-0623-ZP86-SUB33 HLA-A*02 CB-C182 NLVPMVATV
XS-0623-ZP86-SUB34 HLA-A*02 CB-C183 NLVPMVATV
XS-0623-ZP86-SUB35 HLA-A*02 CB-C184 NLVPMVATV
XS-0623-ZP86-SUB36 HLA-A*02 CB-C185 NLVPMVATV
XS-0623-ZP86-SUB37 HLA-A*02 CB-C186 NLVPMVATV
XS-0623-ZP86-SUB38 HLA-A*02 CB-C187 NLVPMVATV
XS-0623-ZP86-SUB39 HLA-A*02 CB-C188 NLVPMVATV
XS-0623-ZP86-SUB40 HLA-A*02 CB-C189 NLVPMVATV
XS-0623-ZP86-SUB41 HLA-A*02 CB-C190 NLVPMVATV
XS-0623-ZP86-SUB42 HLA-A*02 CB-C191 NLVPMVATV
XS-0623-ZP86-SUB43 HLA-A*02 CB-C192 NLVPMVATV
XS-0623-ZP86-SUB44 HLA-A*02 CB-C193 NLVPMVATV
XS-0623-ZP86-SUB45 HLA-A*02 CB-C194 NLVPMVATV
XS-0623-ZP86-SUB46 HLA-A*02 CB-C195 NLVPMVATV
XS-0623-ZP86-SUB47 HLA-A*02 CB-C196 NLVPMVATV
XS-0623-ZP86-SUB48 HLA-A*02 CB-C197 NLVPMVATV

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-pp65 TCR-NK Cells (XS-0623-ZP86). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.